Vascular endothelial growth factor antibody conjugated iron oxide nanoparticles for in vivo tumor targeting and imaging

• Main Authors: Wan-Ju Hsieh, 謝琬汝
• Other Authors: 陳玉怜
• Format: Others
• Language: zh-TW
• Published: 2011
• Online Access: http://ndltd.ncl.edu.tw/handle/51764240169948391099

碩士 === 國立臺灣大學 === 解剖學暨生物細胞學研究所 === 99 === Magnetic iron oxide (IO) nanoparticles with a long blood retention time, low toxicity, and biodegradability can be engineered to link tumor-targeting ligands for diagnostic imaging. Upregulation of vascular endothelial growth factor (VEGF) is found in many cancer types, which provides an opportunity for designing antibody-targeted approaches for cancer detection and treatment. To determine if the systemic delivery of nanoparticles leads to target specific accumulation into the VEGF-expressing tumor mass in vivo, we injected the VEGF Ab-conjugated IO nanoparticles, which have the superparamagnetic property, through the jugular vein into the balb/c mice bearing colon cancer from the VEGF-positive mouse colon cancer cell line, CT 26. Magnetic resonance imaging (MRI) scan showed the significant decrease of significant T*2 signal and T2 relaxation in the VEGF Ab conjugated IO nanoparticles injected-mice but not in IO nanoparticles-treated mice. Examination of paraffin sections of tumor tissues revealed strong blue reaction obtained from the mice that received VEGF Ab conjugated nanoparticles, but low reaction was found in mice with IO nanoparticles alone injection by Prussian blue staining. A lot of VEGF Ab-conjugated IO nanopartices were present in cells and extracellular matrix in tumor tissues than IO nanoparticle-injected mice by transmission electron microscopy. The present study demonstrated that efficient accumulation of VEGF Ab conjugated IO nanoparticles into tumor cells after systemic delivery. These results suggested that VEGF Ab conjugated IO nanoparticles can be used for the targeted delivery of therapeutic agents.